- Research works
- 66 ▲ 89% vs 2013–17
- Citations
- 1.1k 16.0 per fractional work
- Top-10% rate
- 22.4% record average 16.5%
- Open access
- 27% world 28%
Not ranked overall: Mersana Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 14.0×. Every wedge is a field page.
Who are the top researchers at Mersana Therapeutics (United States)?
Ranked on the composite score, Scott D. Collins, Rebecca Mosher and Natalya D. Bodyak lead among researchers whose main affiliation is Mersana Therapeutics (United States).
- 1 Scott D. Collins United States · #372,748 worldwide 163 citations · 19 works
- 2 Rebecca Mosher United States · #503,583 worldwide 46 citations · 19 works
- 3 Natalya D. Bodyak United States · #1,245,476 worldwide 50 citations · 20 works
- 4 Marc Damelin United States · #1,379,512 worldwide 21 citations · 29 works
- 5 LiuLiang Qin United States · #1,482,208 worldwide 14 citations · 19 works
- 6 Timothy B. Lowinger United States · #1,546,232 worldwide 11 citations · 25 works
- 7 Joshua D. Thomas United States · #1,592,412 worldwide 7 citations · 22 works
- 8 Kalli C. Catcott United States · #1,611,617 worldwide 4 citations · 20 works
- 9 Mao Yin United States · #1,614,037 worldwide 7 citations · 15 works
Which keywords describe research at Mersana Therapeutics (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors, Breast Cancer and Metastatic.
- Chimeric Antigen Receptor
- Biomarkers
- Immunosuppression
- Angiogenesis
- Bacterial Therapy
- Clinical Trials
- Interferon Signaling
- Gene Therapy
- Innate Immunity
- Neurotoxicity
- Tumor Microenvironment
- Cancer Therapy
- Metastatic Breast Cancer
- Radioimmunotherapy
- PET Imaging
- Trastuzumab
- Metastatic
- Fc Receptors
- Therapeutic Antibodies
- Glycosylation
- Chemotherapy
- Monoclonal Antibodies
- Antibody Engineering
- Breast Cancer
- HER2
- Immunotherapy
- Targeted Therapy
- Radiopharmaceuticals
- Tumor Regression
- Quality of Life
- Chemotherapy-Induced Peripheral Neuropathy
- Taxanes
- Tumor Targeting
- Pattern Recognition Receptors
- Viral Infection
- Arginine Deprivation
- Cancer Immunotherapy
- Fibroblast Activation Protein
- Metastasis
- CAR T Cells
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy15▲ 32×7 topics
- Glycosylation12▲ 85×2 topics
- Monoclonal Antibodies12▲ 129×3 topics
- Therapeutic Antibodies12▲ 144×2 topics
- Antibody Engineering12▲ 178×1 topic
- Fc Receptors12▲ 178×1 topic
- Breast Cancer11▲ 58×3 topics
- Metastatic11▲ 252×2 topics
- HER210▲ 521×1 topic
- Trastuzumab10▲ 369×1 topic
- Immunotherapy8▲ 19×8 topics
- PET Imaging7▲ 47×2 topics
- Targeted Therapy6▲ 45×4 topics
- Radioimmunotherapy4▲ 168×1 topic
- Radiopharmaceuticals4▲ 168×1 topic
- Metastatic Breast Cancer4▲ 99×2 topics
- Tumor Regression4▲ 74×2 topics
- Cancer Therapy4▲ 10×6 topics
- Quality of Life4▲ 4.8×3 topics
- Tumor Microenvironment4▲ 18×7 topics
- Chemotherapy-Induced Peripheral Neuropathy4▲ 123×1 topic
- Neurotoxicity4▲ 34×2 topics
- Taxanes4▲ 123×1 topic
- Innate Immunity4▲ 17×3 topics
- Tumor Targeting4▲ 45×3 topics
- Gene Therapy4▲ 21×3 topics
- Pattern Recognition Receptors4▲ 37×2 topics
- Interferon Signaling3▲ 151×1 topic
- Viral Infection3▲ 67×1 topic
- Clinical Trials3▲ 7.0×4 topics
- Arginine Deprivation2▲ 86×1 topic
- Bacterial Therapy2▲ 86×1 topic
- Cancer Immunotherapy2▲ 26×2 topics
- Angiogenesis2▲ 8.5×2 topics
- Fibroblast Activation Protein2▲ 67×1 topic
- Immunosuppression2▲ 30×1 topic
- Metastasis2▲ 10×4 topics
- Biomarkers2▲ 5.4×2 topics
- CAR T Cells2▲ 61×1 topic
- Chimeric Antigen Receptor2▲ 61×1 topic
Which research topics does Mersana Therapeutics (United States) publish most on?
By volume in 2022–2025: Monoclonal and Polyclonal Antibodies Research, interferon and immune responses, HER2/EGFR in Cancer Research and Peptidase Inhibition and Analysis.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
- 2 interferon and immune responses Immunology 2 works
- 3 HER2/EGFR in Cancer Research Oncology 2 works
- 4 Peptidase Inhibition and Analysis Oncology 1 works
- 5 Virus-based gene therapy research Genetics 1 works
- 6 Cancer Research and Treatments Biotechnology 1 works
- 7 Ovarian cancer diagnosis and treatment Reproductive Medicine 1 works
- 8 Neuroblastoma Research and Treatments Neurology 1 works
- 9 Cancer Treatment and Pharmacology Oncology 0 works
- 10 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Mersana Therapeutics (United States)'s research output changed?
Output in 2018–2022 was 89% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Cambridge
- Harvard University
- Massachusetts Institute of Technology
- Center for Astrophysics Harvard & Smithsonian
- National Bureau of Economic Research
- IIT@MIT
- World Wide Web Consortium
- Broad Institute
- Smithsonian Astrophysical Observatory
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.